Amani Daoud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amani Daoud has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Eyal Sela
Department of Otolaryngology–Head and Neck Surgery Galilee Medical Center Nahariya Israel
4 shared publicationsTal Marshak
Department of Otolaryngology–Head and Neck Surgery Galilee Medical Center Nahariya Israel
4 shared publications- Ohad Ronen
Azrieli Faculty of Medicine Bar‐Ilan University Safed Israel
3 shared publications Amiel Dror
Department of Otolaryngology, Head and Neck Surgery Galilee Medical Center Nahariya Israel
2 shared publicationsShiri Geva
Department of Otolaryngology–Head and Neck Surgery Galilee Medical Center Nahariya Israel
2 shared publications- Amiel A. Dror
Department of Otolaryngology–Head and Neck Surgery Galilee Medical Center Nahariya Israel
1 shared publication
Latest Publications
- 3 July 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 175 (3) , 571-577
Medial Flap Versus Coblation‐Assisted Turbinoplasty For Turbinates Hypertrophy: A Prospective Randomized Controlled Trial
Objective: Inferior turbinate (IT) hypertrophy is a common cause of nasal obstruction. Surgical intervention may be required when medical treatment fails. This study compares the long‐term efficacy of medial‐flap turbinoplasty (MFT) and coblation‐assisted turbinoplasty (CAT) in patients with persistent nasal obstruction. Study Design: A prospective, randomized controlled trial. Setting: Otolaryngology department—hospital and ambulatory clinics. Methods: Patients with IT hypertrophy who were surgical candidates were assigned to undergo either MFT or CAT. Symptom severity was assessed using the NOSE scale and VAS for nasal obstruction at baseline and at 1, 3, 6, and 12 months postoperatively. Secondary outcomes included endoscopic assessment of turbinate size, postoperative complications, and pain. Outcome examiners were blinded to the surgical technique. Results: Forty‐four patients completed the study (MFT: 21; CAT: 23). Both groups showed significant symptom improvement at all time points ( P < .0001). While early outcomes were similar, the MFT group demonstrated significantly greater long‐term symptom relief at 12 months (NOSE: 18.5 vs 34.5, P = .027; VAS: 2.2 vs 4.0, P = .043). MFT also showed greater turbinate size reduction ( P < .001) and was associated with significantly less postoperative crusting. Pain scores and recovery times were comparable between groups. Conclusion: Both MFT and CAT are effective in improving nasal breathing in patients with IT hypertrophy. However, MFT demonstrated superior long‐term outcomes and fewer complications, supporting this technique in appropriately selected patients.
- 3 July 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 175 (3) , 571-577
Medial Flap Versus Coblation‐Assisted Turbinoplasty For Turbinates Hypertrophy: A Prospective Randomized Controlled Trial
Objective: Inferior turbinate (IT) hypertrophy is a common cause of nasal obstruction. Surgical intervention may be required when medical treatment fails. This study compares the long‐term efficacy of medial‐flap turbinoplasty (MFT) and coblation‐assisted turbinoplasty (CAT) in patients with persistent nasal obstruction. Study Design: A prospective, randomized controlled trial. Setting: Otolaryngology department—hospital and ambulatory clinics. Methods: Patients with IT hypertrophy who were surgical candidates were assigned to undergo either MFT or CAT. Symptom severity was assessed using the NOSE scale and VAS for nasal obstruction at baseline and at 1, 3, 6, and 12 months postoperatively. Secondary outcomes included endoscopic assessment of turbinate size, postoperative complications, and pain. Outcome examiners were blinded to the surgical technique. Results: Forty‐four patients completed the study (MFT: 21; CAT: 23). Both groups showed significant symptom improvement at all time points ( P < .0001). While early outcomes were similar, the MFT group demonstrated significantly greater long‐term symptom relief at 12 months (NOSE: 18.5 vs 34.5, P = .027; VAS: 2.2 vs 4.0, P = .043). MFT also showed greater turbinate size reduction ( P < .001) and was associated with significantly less postoperative crusting. Pain scores and recovery times were comparable between groups. Conclusion: Both MFT and CAT are effective in improving nasal breathing in patients with IT hypertrophy. However, MFT demonstrated superior long‐term outcomes and fewer complications, supporting this technique in appropriately selected patients.
- 23 May 2026
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (11) , 842-849
Safety and Efficacy of a Novel Radiofrequency Device for Submucosal Turbinate Reduction - A Prospective, Open-Label Pilot Trial
Objective: Inferior turbinate (IT) hypertrophy is a major cause of nasal obstruction. Although surgical intervention is effective, it can be associated with morbidity and prolonged recovery. This study evaluated the safety, efficacy, and tolerability of a novel submucosal fractional radiofrequency (FRF) treatment. Methods: A prospective, single-arm, open-label study was conducted from March to November 2024. Patients with nasal obstruction caused by IT hypertrophy unresponsive to at least 1 month of medical treatment were included in the study. The procedure was performed endoscopically under topical anesthesia using FRF. Outcomes were assessed using the Nasal Obstruction Symptom Evaluation (NOSE) scale, Visual Analog Scale (VAS), and endoscopic turbinate grading at baseline, 1 month, and 3 months after the procedure. The safety outcomes included pain scale, adverse events, and complications. Results: A total of 22 patients completed the protocol. The NOSE score improved from 71.2 to 30.0 at 1 month ( P < .001). Sustained NOSE score improvement was observed at 3 months (37.1, P < .001). The VAS scores for nasal obstruction decreased from 7.4 to 3.2 at 1 month and 3.9 at 3 months ( P < .0001). Endoscopic grading of turbinate size demonstrated a reduction at both follow-up points ( P < .05). The average VAS score for pain was 3.4, indicating good tolerability. No bleeding, synechiae, or other adverse events were reported. Crusting appeared in 50% of patients at 1 month, resolving in all but 1 patient by 3 months. A significant correlation was observed between the pulse count and symptom improvement ( P = .02). Conclusion: Submucosal FRF treatment leads to significant and sustained improvement in nasal obstruction with minimal pain and no major adverse events. These results support the safety, efficacy, and tolerability of the procedure for IT hypertrophy in an outpatient setting. Larger cohorts and long-term follow-up studies are warranted to refine the treatment and further validate these findings. Level of evidence: 3
- 23 May 2026
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (11) , 842-849
Safety and Efficacy of a Novel Radiofrequency Device for Submucosal Turbinate Reduction - A Prospective, Open-Label Pilot Trial
Objective: Inferior turbinate (IT) hypertrophy is a major cause of nasal obstruction. Although surgical intervention is effective, it can be associated with morbidity and prolonged recovery. This study evaluated the safety, efficacy, and tolerability of a novel submucosal fractional radiofrequency (FRF) treatment. Methods: A prospective, single-arm, open-label study was conducted from March to November 2024. Patients with nasal obstruction caused by IT hypertrophy unresponsive to at least 1 month of medical treatment were included in the study. The procedure was performed endoscopically under topical anesthesia using FRF. Outcomes were assessed using the Nasal Obstruction Symptom Evaluation (NOSE) scale, Visual Analog Scale (VAS), and endoscopic turbinate grading at baseline, 1 month, and 3 months after the procedure. The safety outcomes included pain scale, adverse events, and complications. Results: A total of 22 patients completed the protocol. The NOSE score improved from 71.2 to 30.0 at 1 month ( P < .001). Sustained NOSE score improvement was observed at 3 months (37.1, P < .001). The VAS scores for nasal obstruction decreased from 7.4 to 3.2 at 1 month and 3.9 at 3 months ( P < .0001). Endoscopic grading of turbinate size demonstrated a reduction at both follow-up points ( P < .05). The average VAS score for pain was 3.4, indicating good tolerability. No bleeding, synechiae, or other adverse events were reported. Crusting appeared in 50% of patients at 1 month, resolving in all but 1 patient by 3 months. A significant correlation was observed between the pulse count and symptom improvement ( P = .02). Conclusion: Submucosal FRF treatment leads to significant and sustained improvement in nasal obstruction with minimal pain and no major adverse events. These results support the safety, efficacy, and tolerability of the procedure for IT hypertrophy in an outpatient setting. Larger cohorts and long-term follow-up studies are warranted to refine the treatment and further validate these findings. Level of evidence: 3
- 7 June 2023
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 71, 74-80
Decline in emergency department visits during the COVID-19 quarantine
- 7 June 2023
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 71, 74-80
Decline in emergency department visits during the COVID-19 quarantine
- Open Access
- 1 December 2022
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 8 (1) , 34-39
Cross‐cultural adaptation of the Hebrew Nasal Obstruction Symptom Evaluation (NOSE) scale
Objective: Nasal obstruction is a common complaint. The Nasal Obstruction Symptom Evaluation scale (NOSE) is a reliable validated tool used to assess the quality of life of patients with nasal obstruction. The purpose of this study is to validate the Hebrew version of the NOSE scale (He‐NOSE).Methods: A prospective instrument validation was conducted. The NOSE scale was translated primarily from English to Hebrew and then back from Hebrew to English according to the accepted guidelines of the cross‐cultural adaptation process. The study group included surgery candidates suffering from nasal obstruction due to a deviated nasal septum and/or inferior turbinate hypertrophy. The study group completed the validated He‐NOSE questionnaire twice prior to the surgery and once again, a month post‐surgery. A control group of individuals with no history of nasal complaints or surgeries was asked to complete the questionnaire once. Reliability, internal consistency, validity, and responsiveness to change of the He‐NOSE were evaluated.Results: Fifty‐three patients and 100 controls were included in this study. The scale showed excellent ability to discriminate between the study and the control group, exhibiting significantly lower scores in the control group (73.8 and 7 average scores respectively, p < .001). Good internal consistency (Cronbach's alpha .71 and .76) and test–retest reliability (Spearman rank correlation r = .752, p < .0001) were measured. Moreover, the scale revealed remarkable responsiveness to change (p < .00001).Conclusion: The translated and adapted He‐NOSE scale can be a useful tool to be applied in both clinical and research fields when assessing nasal obstruction.Level of evidence: N/A.
- 1 December 2022
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 8 (1) , 34-39
Open AccessCross‐cultural adaptation of the Hebrew Nasal Obstruction Symptom Evaluation (NOSE) scale
Objective: Nasal obstruction is a common complaint. The Nasal Obstruction Symptom Evaluation scale (NOSE) is a reliable validated tool used to assess the quality of life of patients with nasal obstruction. The purpose of this study is to validate the Hebrew version of the NOSE scale (He‐NOSE).Methods: A prospective instrument validation was conducted. The NOSE scale was translated primarily from English to Hebrew and then back from Hebrew to English according to the accepted guidelines of the cross‐cultural adaptation process. The study group included surgery candidates suffering from nasal obstruction due to a deviated nasal septum and/or inferior turbinate hypertrophy. The study group completed the validated He‐NOSE questionnaire twice prior to the surgery and once again, a month post‐surgery. A control group of individuals with no history of nasal complaints or surgeries was asked to complete the questionnaire once. Reliability, internal consistency, validity, and responsiveness to change of the He‐NOSE were evaluated.Results: Fifty‐three patients and 100 controls were included in this study. The scale showed excellent ability to discriminate between the study and the control group, exhibiting significantly lower scores in the control group (73.8 and 7 average scores respectively, p < .001). Good internal consistency (Cronbach's alpha .71 and .76) and test–retest reliability (Spearman rank correlation r = .752, p < .0001) were measured. Moreover, the scale revealed remarkable responsiveness to change (p < .00001).Conclusion: The translated and adapted He‐NOSE scale can be a useful tool to be applied in both clinical and research fields when assessing nasal obstruction.Level of evidence: N/A.
- 27 October 2021
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 136 (5) , 427-432
Inferior turbinate reduction: comparing post-operative bleeding between different surgical techniques
Objective: Post-operative bleeding is one of the most common and severe complications of turbinate surgery. This study compared post-operative bleeding following partial turbinectomy, submucosal turbinate reduction and endoscopic turbinoplasty. Methods: Post-operative bleeding was assessed in patients who underwent inferior turbinate intervention by partial turbinectomy, submucosal turbinate reduction or endoscopic turbinoplasty between January 2016 and November 2017 and had completed at least one month of follow up. Results: Of 1035 patients who underwent inferior turbinate surgery during the study period, 751 were included. Of these, 56 (7.5 per cent) presented to the emergency room with post-operative bleeding; 31 (8.4 per cent) had undergone partial turbinectomy, 19 (10.7 per cent) had undergone submucosal turbinate reduction and 6 (3.0 per cent) had undergone endoscopic turbinoplasty. The odds ratio of requiring an intervention to control bleeding was significantly lower in the endoscopic turbinoplasty group than in the submucosal turbinate reduction group (odds ratio = 3.26, 95 per cent confidence interval = 1.02–10.43). Conclusion: Endoscopic turbinoplasty had the lowest rate of post-operative bleeding and the lowest rate of patients requiring intervention.
- 27 October 2021
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 136 (5) , 427-432
Inferior turbinate reduction: comparing post-operative bleeding between different surgical techniques
Objective: Post-operative bleeding is one of the most common and severe complications of turbinate surgery. This study compared post-operative bleeding following partial turbinectomy, submucosal turbinate reduction and endoscopic turbinoplasty. Methods: Post-operative bleeding was assessed in patients who underwent inferior turbinate intervention by partial turbinectomy, submucosal turbinate reduction or endoscopic turbinoplasty between January 2016 and November 2017 and had completed at least one month of follow up. Results: Of 1035 patients who underwent inferior turbinate surgery during the study period, 751 were included. Of these, 56 (7.5 per cent) presented to the emergency room with post-operative bleeding; 31 (8.4 per cent) had undergone partial turbinectomy, 19 (10.7 per cent) had undergone submucosal turbinate reduction and 6 (3.0 per cent) had undergone endoscopic turbinoplasty. The odds ratio of requiring an intervention to control bleeding was significantly lower in the endoscopic turbinoplasty group than in the submucosal turbinate reduction group (odds ratio = 3.26, 95 per cent confidence interval = 1.02–10.43). Conclusion: Endoscopic turbinoplasty had the lowest rate of post-operative bleeding and the lowest rate of patients requiring intervention.